Aveanna Healthcare Upgraded to Outperform with 50.7% Upside to $10.05
AVAH•Aveanna Healthcare Holdings received an Outperform rating upgrade from RBC Capital, citing its stock trading around $6.47 and a $10.05 consensus target implying 50.7% upside. The company trimmed debt leverage from over 11x at end-2022 to under 3.8x by Q1 2023.
1. Rating Upgrade by RBC Capital
RBC Capital raised its rating for Aveanna Healthcare to Outperform from Sector Perform when the stock traded at $6.47, reflecting increased confidence in the company’s strategic transformation and financial positioning.
2. Debt Leverage Improvement
Aveanna Healthcare reduced its debt-to-EBITDA ratio from over 11 times at the end of 2022 to below 3.8 times by the end of Q1 2023, strengthening its balance sheet and lowering financial risk.
3. Acquisition and Growth Outlook
The acquisition of Family First Homecare added 27 locations across seven states, bolstering service capacity and supporting Aveanna’s raised 2026 revenue growth target of 7% to 10%, following a 10% CAGR over the past six years.
4. Analyst Price Targets and Upside
Wall Street analysts set a consensus price target of $10.05, implying 50.7% upside from current levels, with individual forecasts ranging from $8.00 to $13.00 based on ten short-term estimates.
